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Inclusion body myopathy associated with Paget’s disease of bone and frontotemporal dementia (IBMPFD) is a
dominantly inherited degenerative disorder caused bymutations in the valosin-containing protein (VCP) gene.
VCP (p97 in mouse, TER94 in Drosophila melanogaster and CDC48 in Saccharomyces cerevisiae) is a highly
conserved AAA1-ATPase that regulates a wide array of cellular processes. The mechanism of IBMPFD patho-
genesis is unknown. Towards elucidating the pathogenic mechanism we have developed and characterized
transgenic mice with ubiquitous expression of wild-type and disease-causing versions of human VCP/p97.
Here, we report that mice expressing VCP/p97 harboring the mutations R155H or A232E develop pathology
that is limited to muscle, brain and bone, recapitulating the spectrum of disease in humans with IBMPFD.
Themice exhibit progressivemuscle weakness and pathological examination ofmuscle shows classic charac-
teristics of inclusion body myopathy including rimmed vacuoles and TDP-43 pathology. The mice exhibit
abnormalities in behavioral testing and pathological examination of the brain shows widespread TDP-43 path-
ology. Furthermore, radiological examination of the skeleton reveals thatmutantmice develop severe osteope-
nia accompanied by focal lytic and sclerotic lesions in vertebrae and femur. In vitro studies indicate thatmutant
VCP causes inappropriate activation of the NF-kBsignaling cascade, which could contribute to themechanism
of pathogenesis in multiple tissues including muscle, bone and brain.
INTRODUCTION
Inclusion body myopathy with Paget’s disease of bone and
frontotemporal dementia (IBMPFD) is a rare, autosomal domi-
nant disorder characterized by the presence of at least three
distinct disease pathologies of variable penetrance within a
given kindred (1). Each of these disease pathologies—
inclusion body myopathy (IBM), Paget’s disease of bone
(PDB) and frontotemporal dementia (FTD)—also exists indi-
vidually as a common sporadic disorder. Muscle weakness
with mild to severe myopathy is the most common clinical
feature in IBMPFD, present in 80–90% of affected individ-
uals. Radiographic and biochemical abnormalities consistent
with PDB are observed in 43–51% of IBMPFD patients,
although the age of onset (42 years) is earlier than its
sporadic counterpart. The dementia in IBMPFD is typical of
FTD-TDP and is characterized by language and behavioral
abnormalities, and typically presents later than both the IBM
and PDB with a mean age of onset of 54 years (2).
IBMPFD is caused by mutations in the gene valosin-containing
protein (VCP/p97) (3). Arginine 155 is the most common amino
acid affected, with mutations at this position occurring in more
than 50% of IBMPFD families. Substitution of this arginine
residue to histidine (R155H) is the most common VCP mutation
linked to IBMPFD. Mutation of alanine 232 to glutamic acid
(A232E) is associated with a more severe clinical presentation,
characterized by earlier onset of paget’s disease of bone and a par-
ticularly aggressive myopathy. To date, a total of 14 VCP gene
mutations have been reported in more than twenty families (3–8).
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VCP is a type II AAAþ protein (ATPase Associated
with diverse cellular Activities). VCP activity is essential for
multiple aspects of ubiquitin-dependent signaling, including
proteasome-mediated degradation of regulatory proteins such
as IkB-a. Knockout of murine VCP/p97 results in early embryo-
nic lethality, underscoring the importance of this gene’s activity
(9). The diversity in VCP/p97 activities reflects its ability to
interact with a diverse array of adaptor proteins via N-terminal
adaptor-binding domain. Most disease-causing mutations in
VCP span the interface of the N-terminal domain and the D1
ATPase domain, leading to speculation about interference
with a subset of adaptor-dependent interactions, although this
as yet to be substantiated by evidence (10). The dominant
mode of inheritance in IBMPFD suggests a toxic gain of func-
tion and this notion is supported evidence that disease-causing
VCP mutations actually increase ATPase activity relative to
wild-type, although a dominant negative mechanism cannot
be excluded (11). The precise mechanism whereby mutations
in VCP result in IBMPFD is unknown, and the basis for the
selective vulnerability of brain, muscle and bone remains
elusive although recent reports indicate that disease mutations
in VCP compromise autophagy (12,13).
IBMPFD pathology is characterized by nuclear and cyto-
plasmic inclusions that are ubiquitin-positive but
VCP-negative (14). These inclusions are immunopositive for
the protein TAR DNA-binding protein 43 (TDP-43), a
feature that links this pathology to a broad array of sporadic
and inherited diseases including frontotemporal lobar degener-
ation with TDP-43 pathology (FTLD-TDP) and amyotrophic
lateral sclerosis (ALS) (15). In these diseases, TDP-43 redistri-
butes from the nucleus to the cytoplasm, and this change in
subcellular localization correlates with cellular toxicity.
Aspects of the muscle pathology in IBMPFD have been pre-
viously modeled by transgenic expression of VCP with the
R155H mutation under control of the muscle creatine kinase
promoter (16). However, there remains a need for an animal
model that captures the full spectrum of pathologies seen in
IBMPFD, including involvement of muscle, brain and bone.
Here, we demonstrate that transgenic mice with ubiquitous
transgenic expression of mutant VCP recapitulate all aspects
of IBMPFD including IBM with TDP-43 pathology, cognitive
abnormalities accompanied by widespread TDP-43 pathology
in brain, and bone abnormalities with similarities to PDB.
Despite widespread expression in other tissues—including
heart, liver, kidney, spleen and gut—this is not associated
with pathology. In addition, we show that mutant VCP accel-
erates the turnover of IkB-a, leading to inappropriate acti-
vation of the NF-kB signaling cascade, which could
contribute to the mechanism of pathogenesis in multiple
tissues including muscle, bone and brain.
RESULTS
Generation and characterization of transgenic mice
To generate mice expressing VCP in all tissues, human VCP
cDNA was expressed under the control of the CMV-enhanced
chicken beta-actin promoter. This promoter has been shown to
drive robust transgene expression in all tissues, permitting us
to explore the consequences of widespread mutant VCP
expression in a single animal including muscle, brain and
bone which are tissues affected in IBMPFD (17–19). The
disease-associated mutations R155H and A232E were intro-
duced to wild-type human VCP by site-directed mutagenesis.
These represent the most common and most severe disease-
causing mutations, respectively.
Founder mice were generated by pronuclear injection and
screened by PCR genotyping of tail DNA, resulting in four
lines of VCP-wild-type (VCP-wt), five lines of VCP-R155H
and five lines of VCP-A232E mice. VCP expression was eval-
uated in each line by western blot analysis and expression-
matched lines were chosen for further study. The transgenic
lines evaluated and presented here correspond to VCP-wt#7,
VCP-R155H#55 and VCP-A232E#93 (hereafter, referred to
as VCP-wt, VCP-R155H and VCP-A232E, respectively).
Western blot analysis of VCP protein levels from muscle,
brain and bone in these animals shows expression of VCP at
2–3-fold relative to endogenous levels (Fig. 1A). The
animals were backcrossed onto the C57/B6 background, yield-
ing the expected Mendelian ratios of transgene positive pups
and F3 progeny were analyzed for evidence of the IBMPFD
phenotype.
As we expected in a model of this adult-onset disorder,
wild-type and mutant mice developed normally initially, but
both VCP-R155H and VCP-A232E mice began to show
adult-onset weight loss at 9 months of age and continued
to decline in weight relative to their non-transgenic and
VCP-wt counterparts (Fig. 1B). Beginning at 3–6 months of
age, some VCP-R155H and VCP-A232E mice show a hind-
limb clasping phenotype (Fig. 1C), which increased in severity
and penetrance over time (Supplementary Material, Fig. S1A
and B). This dyskinetic clasping posture is present in numer-
ous mouse models of neurodegenerative disease and is a
non-specific indicator of CNS pathology (20,21). Mice were
followed until 15 months of age, and both VCP-R155H and
VCP-A232E mice demonstrated a statistically significant
decrease in survival as seen by Kaplan–Meier analysis
(Fig. 1D). End-stage disease was characterized by a brief
period of rapid weight loss, often accompanied by hind-limb
paresis and animals were euthanized when weight loss
reached 20% of maximal body weight or when decreased
hind limb mobility hindered feeding and watering behaviors.
VCP mutant mice develop muscle weakness and
histopathological signs of IBM including rimmed vacuoles
and TDP-43 and ubiquitin-positive pathology
To determine whether mice expressing VCP-R155H and
VCP-A232E would develop an IBM phenotype, mice were
monitored for signs of muscle weakness by analysis of grip-
strength using the well-established hanging wire test. Briefly,
mice were suspended by their front limbs from a wire and
the latency to fall was recorded with a maximum of 200 s per-
mitted. Mice were tested every 4 weeks beginning at weaning.
By 16 weeks of age, VCP-A232E mice showed a significant
deficit in hanging wire performance compared with wild-type
and non-transgenic controls (Fig. 2A). By 20 weeks of age,
both VCP-A232E and VCP-R155H mice showed significant
deficits in hanging wire performance. The earlier onset of
muscle weakness in VCP-A232E mice is in accordance with
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the clinical presentation of the A232E mutations in humans, in
which a more severe phenotype has been reported (22).
Histological analyses of quadriceps and gastrocnemius
muscle taken from 9-month-old animals showed evidence of
myogenic myopathy including irregular fiber size, centralized
nuclei and inflammatory infiltrates (Fig. 2B–G and data not
shown). In addition, modified Gomori trichrome staining
revealed the presence of rimmed vacuoles in muscle from
both VCP-R155H and VCP-A232E mice (Fig. 3E and data
not shown), a hallmark of the degeneration seen in IBMPFD
muscle, as well as sporadic IBM and other hereditary forms
of IBM (23,24). Immunohistochemical examination of
muscle from IBMPFD patients shows TDP-43 pathology in
the form of cytoplasmic aggregates (25,26). Consistent with
these observations, we observed cytoplasmic accumulation
of TDP-43 in muscle from both VCP-R155H and
VCP-A232E mice (Fig. 3A–D). Immunostaining of serial sec-
tions revealed that these cytoplasmic accumulations of
TDP-43 are also ubiquitin-positive (Fig. 3F). Despite robust
transgene expression as determined by western blot analysis,
liver, kidney, spleen and intestine from IBMPFD mice
appear histologically normal, and blood chemistries reveal
no evidence of liver or kidney dysfunction (Supplementary
Material, Fig. S3). VCP/p97 transgene expression was distrib-
uted evenly throughout the muscle fibers, and no correlation
was seen between the level of VCP expression per fiber and
fiber integrity (Supplementary Material, Fig. S4).
Ultrastructural analysis of quadriceps and gastrocnemius
muscle from VCP-R155H and VCP-A232E mice by TEM
revealed severely disorganized sarcomeres scattered among
more normal-appearing sarcomeres best appreciated in the
longitudinal plane (Fig. 4A–D and data not shown). When
examined in cross-section, sarcomeres from VCP mutant
mice frequently showed loss of myofilament integrity
(Fig. 4E and F). These myofiber abnormalities in
VCP-R155H and VCP-A232E mice were accompanied by
abnormal mitochondria scattered among more normal-
appearing mitochondria. The abnormal mitochondria exhib-
ited marked pleioconia and megaconia (Fig. 4C and D).
VCP has been implicated as playing an important role in
regulating myofibrillogenesis through regulating the steady
state levels of the muscle-specific chaperone protein Unc45b
(27). Dysregulation of Unc45b levels leads to defects if myo-
fibrillogenesis in multiple animal model systems (28,29).
Figure 1. Generation of a mouse model of IBMPFD. (A) Tissue lysates from 8-week-old male mice were isolated from muscle, brain and bone and VCP protein
levels were measured by western blotting with a monoclonal VCP antibody. Quantification of bands from three separate experiments reveals 2-fold transgenic
VCP expression relative to endogenous. (B) Mice were weighed every 2 months (only males are shown) and begin to show statistically significant weight loss at
8 months of age for VCP-A232E mice and 10 months of age for VCP-R155H. (C) When suspended by the tail, VCP mutant mice demonstrate the classical
clasping response with both fore and hind limbs. (D) 18 non-transgenic mice and 20 mice from each VCP transgenic genotype were followed longitudinally
for 15 months. Kaplan–Meier analysis shows that both VCP-A232E and VCP R155H lines show increased mortality relative to wild-type or non-transgenic
controls (P, 0.05). Survival was analyzed by Kaplan–Meier, and body mass was analyzed by one-way ANOVA followed by post hoc Tukey’s t-test.
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Disease-causing mutations in VCP were shown to stabilize
Unc45b levels in vitro, implicating this as a contributing
factor to myopathy in IBMPFD (29). Consistent with these
data, muscle lysates from VCP-R155H and VCP-A232E
mice showed significantly increased steady-state levels of
Unc45b protein compared with wild-type and non-transgenic
controls, with a more prominent stabilization observed in the
more severely affected VCP-A232E muscle (Fig. 4G). These
increased levels of Unc45b are consistent with a mechanism
in which overactive myosin remodeling contributes to the
loss of the sarcomere integrity seen by TEM.
VCP mutant mice develop behavior abnormalities as well
as TDP-43- and ubiquitin-positive pathology
IBMPFD patient brain tissue is characterized by ubiquitin- and
TDP-43-positive pathology in the form of intranuclear and
cytoplasmic inclusions and accumulation in dystrophic neur-
ites (30). TDP-43 is also the major disease protein in the ubi-
quitinated inclusions characteristic of both sporadic and
familial forms of frontotemporal lobar degeneration
(FTLD-TDP) as well as ALS. In these diseases, TDP-43 redis-
tributes from the nucleus to cytoplasmic aggregates (15,31).
Brains harvested from VCP transgenic mice at 4, 6, 8, 10,
12 and 14 months of age showed no overt signs of degener-
ation by hematoxylin and eosin stain. First apparent at 14
months of age; however, immunohistochemical staining for
TDP-43 demonstrated nuclear clearance and cytoplasmic
accumulation in widespread brain regions, but not in the hip-
pocampus (Fig. 5) despite strong transgene expression in this
brain region (Supplementary Material, Fig. S3A). Quantifi-
cation of nuclear clearance in cortex and spinal cord motor
neurons reveals that .10% of cells in cortex and 5% of
neurons in spinal cord lack nuclear TDP-43 immunostaining
(Supplementary Material, Fig. S5). At this age areas of mild
gliosis particularly in the cerebellum were also observed
(data not shown). Double-labeled immunofluorescence
showed that these cytoplasmic accumulations of TDP-43 are
ubiquitin-positive, thereby recapitulating a prominent feature
of FTLD-TDP and IBMPFD neuropathology (Fig. 6A–I).
However, no nuclear inclusions immunopositive for TDP-43
or ubiquitin were observed.
We next sought to characterize the behavioral phenotype of
our VCP mice. Increased levels of anxiety have been reported
in numerous transgenic mouse models of dementia including
models of Alzheimer’s disease and tauopathies (32,33) and
so we monitored the VCP mutants for signs of anxiety-
associated behavior. To measure anxiety, we evaluated
behavior of non-transgenic, VCP-wt, VCP-R155H and
VCP-A232E mice on an elevated zero maze at 12, 16, 20,
24 and 48 weeks of age. For testing with an elevated zero
maze, an animal is placed on a circular platform that is
divided into four quadrants. The quadrants alternate between
closed quadrants that are enclosed by 8-in. walls and open
quadrants with only a small lip. The amount of time that an
animal spends in each quadrant is recorded, and significantly
increased time spent in closed quadrants is associated with
increased anxiety (34). Beginning at 16 weeks of age in
VCP-A232E mice and 20 weeks of age in VCP-R155H
mice, we observed significantly increased anxiety relative to
their wild-type and non-transgenic counterparts (Fig. 6J).
Importantly, VCP mutant mice showed no changes in loco-
motor activity at this age that would confound the results
(Supplementary Material, Fig. S2B). The degree of anxiety
was stable after 20 weeks and did not increase at later time
points (Supplementary Material, Fig. S2A).
Figure 2. VCP mutant mice develop muscle weakness and histological signs
of a myogenic pattern of myopathy. (A) Hanging wire performance in male
mice is significantly reduced (P , 0.01) in VCP-A232E mice by 4 months,
and is significantly reduced in VCP-R155H by 6 months. (B–G) H and E
staining of paraffin embedded quadriceps muscle from 9-month-old
paraformaldehyde-perfused non-trasngenic (B) VCP-wt transgenic (C)
VCP-R155H (D and E) and VCP-A232E (F and G) mice shows normal
muscle morphology in VCP-wt tissue, but marked signs of degeneration in
both mutant lines including centralized nuclei (asterisks), irregular fiber size
and inflammatory infiltrates (arrows).
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At 14 months of age, when TDP-43 pathology was first
appreciated, we assessed the animals’ declarative memory
using a novel object recognition task. This task was chosen
because it is considered to be primarily an assessment of
hippocampal-independent learning and memory, and the hip-
pocampus appears to be spared in IBMPFD brains (35). More-
over, novel object recognition deficits have been reported in
multiple mouse models of FTD (36,37). For this task, the
animals were placed in a large enclosure containing two
objects. The animals were allowed to explore the area, and
investigation of the two objects was recorded. After an
interval of 24 h, the animals were placed back in the training
environment, with one of the original objects having been
replaced by a novel object, and the number of visits to each
object was again recorded. The ratio of novel object visits to
training object visits was calculated, with no apparent prefer-
ence for either object resulting in a ratio of 1. At 24 h post-
training, normal mice show a preference for the novel object
Figure 3. VCP mutant mice show skeletal muscle TDP-43 pathology and rimmed vacuoles evident with Gomori trichrome staining. (A) Immunostaining of
paraffin embedded quadriceps from non-transgenic (A), VCP-wt (B), VCP-R155H (C) and VCP-A232E (D) animals at 9 months with a polyclonal TDP-43
antibody shows normal nuclear staining in non-transgenic and VCP-wt tissues, but demonstrates strong cytoplasmic accumulation in both VCP-R155H and
VCP-A232E tissues (C and D). (F) Staining of serial sections shows that these cytoplasmic TDP-43 accumulations are also ubiquitin positive. (E) Modified
trichrome staining in A232E quadriceps shows the presence of rimmed vacuoles (arrows), a hallmark of IBM pathology.
Human Molecular Genetics, 2010, Vol. 19, No. 9 1745
Figure 4. VCP mutant mice show loss of myosin fiber integrity and stabilization of the myosin chaperone protein Unc45b. (A–D) TEM from quadriceps muscle
(20 000) shows marked degeneration of the normal sarcomeric structure in both VCP-R155H (C) and VCP-A232E (D) muscle, and also the accumulation of
swollen, severely degenerated bodies that can be identified as mitochondria by their few remaining intact cristae (arrows). For comparison, normal mitochodria
are marked with white arrow heads. Muscle from non-transgenic and VCP-wt animals appears normal at this age (A and B). (E and F) Cross-sectional views of
mutant muscle show dramatic loss of myosin fibers and accumulation of vacuoles. (G) Western blotting of skeletal muscle lysates from age-matched animals (12
months) shows an increase in Unc45b protein from two separate R155H and A232E animals compared with VCP-wt and non-transgenic controls. (H) Quan-
titative image analysis of Unc45b western blots from three separate experiments shows significant stabilization of Unc45b protein levels compared with
actin loading controls in VCP-R155H and VCP-A232E mice compared with VCP-wt or non-transgenic control animals.
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by visiting it more frequently than the training object (38). At
training, all mice showed no apparent preference for either
object, producing ratios of 1 (Fig. 6K). When presented
with the novel object 24 h post-training, the VCP mutant
mice showed significantly decreased exploration of the novel
object relative to wild-type or non-transgenic animals, sugges-
tive of impairment in non-hippocampal learning and memory
performance. Thus, VCP mutant mice exhibit TDP-43 neuro-
pathology and deficits in multiple neurological tasks.
VCP mutant mice develop severe osteopenia and focal
pagetic lesions
Paget’s disease of bone is a metabolic bone disorder. The
pathogenic process begins with hyperactive bone resorption
by osteoclasts. This activity is followed by a compensatory
increase in osteoblast activity leading to the increased pro-
duction of poorly formed bone. Over an extended period of
time this process results in bone deformities, pain and propen-
sity to fracture. The PDB seen in IBMPFD patients has a much
earlier onset than sporadic PDB, but otherwise follows a
classic pattern of presentation (39).
At 13 months of age, we evaluated non-transgenic, VCP-wt,
VCP-R155H and VCP-A232E mice for signs of skeletal by
X-ray microtomography (mCT) scan at a resolution of
16 mm. The left and right femur from three male mice of
each genotype were dissected and scanned, and quantitative
volumetric analysis was performed. Renderings of sagittal sec-
tions through the mid-shaft of the femur showed dramatic loss
of trabecular structure in both distal and proximal femur
(Fig. 7A and B). Quantification showed decreased trabecular
number and thickness as well as increased trabecular spacing
and Euler number in VCP mutants (Fig. 7C). This loss of tra-
becular structure in VCP mutant mice was also seen through-
out the vertebral column at this age (data not shown). In the
longitudinal mCT scans, it is apparent that in addition to the
osteopenia, VCP mutants show occasional sclerotic lesions
studding the internal surface of the cortical bone (Fig. 7A,
arrows) as well as focal regions of radiolucency that are appar-
ent in ‘red glass’ renderings of distal femur (Fig. 7B, arrows)
which are indicative of focal areas of decreased bone density.
Solid color volume renderings show areas of hypo-
mineralization in patchy regions of cortical bone in the
distal epiphysis (Supplementary Material, Fig. S5).
Cells expressing mutant VCP show increased activation
of NF-kB
VCP/p97 regulates a plethora of cellular processes including
ubiquitin-dependent protein degradation, stress responses,
nuclear envelope reconstruction and Golgi and endoplasmic
reticulum assembly (40). At present it is unclear which of
these processes are impacted by disease-causing mutations in
VCP/p97 and it is likely that multiple normal functions
are affected. Among the well-characterized roles of VCP
is control of the NF-kB pathway through regulation of
ubiquitin-dependent degradation of IkB-a (41–43). The
NF-kB signaling pathway plays a key role in osteoclastogenesis
and is known to be a major player in PDB (44). Osteoclast pre-
cursors express receptor activator of NF-kB (RANK), which is
activated by binding of the ligand RANK-L, produced by osteo-
blasts. RANK-L binding to RANK initiates a signaling cascade
that results in activation of NF-kB resulting in increased
Figure 5. IBMPFD transgenic mice develop ubiquitin- and TDP-43-positive
neuropathology. (A–D) Immunohistochemistry on paraffin embedded brains
from 14-month-old animals reveals loss of the normal nuclear TDP-43 staining
patterns in neurons from cortical layer two-third in both VCP-R155H (C and
D) and VCP-A232E (E and F) brains compared with the normal nuclear stain-
ing seen in non-transgenic (A) and VCP-wt (B) brains. Occasionally,
especially in brains from VCP-A232E animals, this nuclear clearance is
accompanied by cytoplasmic accumulation of tdp-43 (F inset). (G) Two sep-
arate observers, who then ranked the prominence of nuclear clearance,
assessed nuclear clearance of TDP-43. Areas of the brain where no clearance
was seen are represented as 2. Areas that contained nuclear clearance were
graded, with þþþ being prominent nuclear clearance (.10% of cells
counted), þþ being rated as occasional (5–10%) and þ as rare, but present
(,1–5%). Both observers agreed that the nuclear clearance was most promi-
nent in frontal cortex and was completely absent from hippocampus. Moderate
nuclear clearance was seen in the pons, brainstem and lumbar spinal cord.
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Figure 6. VCP mutant neurons show co-localization of cytoplasmic TDP-43 and ubiquitin, and behavioral assays reveal anxiety and memory defects. (A–I)
Double-label immunohistochemistry on frozen sections of mouse cortex reveals the accumulation of TDP-43 (green) and ubiquitin (red) immunopositive cyto-
plasmic inclusions in both VCP-R155H (B, E, H) and VCP-A232E (C, F, I) mice at 14 months. Nuclei are visualized in blue with DAPI. No such staining was
present in VCP-wt brains (A, D, G), which retain their normal nuclear TDP-43 staining and had no detectable ubiquitin positive aggregation. (J) When analyzed
by elevated zero maze, both VCP-R155H and VCP-A232E animals spend increased amounts of time in the closed arms of the maze, indicating increased anxiety
behavior (J black bars) x2 analysis shows that there is a significant effect of mutant VCP on the distribution of time spent in the open versus the closed quadrants
(P, 0.01) and post hoc t-test revealed no significant difference between the VCP-R155H and VCP-A232E animals. (K) At 14 months of age when tested with a
novel object recognition paradigm, mutant mice tested with a trial interval of 24 h, show decreased novel object preference (object ratio ,1) compared with
non-transgenic and VCP-wt controls.
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transcription of osteoclastogenic genes. Two familial forms of
PDB are caused by mutations that impact activation of
NF-kB by RANK-L, including SQSTM1/p62 and osteoprote-
grin, which inhibits RANK-L signaling. PDB-causing mutations
in either of these genes result in increased NF-kB activity,
hyperactive osteoclasts and increased bone resorption (45–48).
Figure 7. VCP mutant mice show loss of trabecular bone and focal Pagetic lesions. (A) High resolution mCT scans of femur at 13 months shows loss of tra-
becular bone in VCP-R155H and VCP-A232E animals compared with VCP-wt and non-transgenic controls. (B) In addition to the obvious loss of trabecular
structure, occasional focal areas of thickening cortical bone can be seen (arrows). Red glass renderings show areas of decreased density in cortical bone
(arrows). (C) Quantitative volumetric assessment of distal trabecular structure shows significant changes on all metrics captured, including decreased trabecular
number, increased trabecular spacing, decreased trabecular thickness and more positive Euler number for VCP mutants compared with VCP-wt and non-
transgenic controls (data were analyzed by one-way ANOVA followed by post hoc t-test between groups. P, 0.05, P , 0.01 when compared with non-
transgenic).
Human Molecular Genetics, 2010, Vol. 19, No. 9 1749
In contrast to the role of NF-kB in bone disease, the role of
NF-kB in muscle disease has only recently been illuminated
and is now implicated as a factor in muscle atrophy in multiple
disease states (49). For example, mice expressing muscle-
specific, constitutively active IKK (‘MIKK mice’) show
increased basal NF-kB activity, and most importantly,
increased NF-kB-dependent muscle degeneration following
disuse. Increased NF-kB signaling leads to increased tran-
scription of the muscle-specific E3 ligase URF1/TRIM63,
which leads to the ubiquitination and subsequent degradation
of myosin fibers, and loss of Murf1 partially rescues the
muscle wasting (50). Thus, hyper-activation of NF-kB signal-
ing has been implicated as an important contributor to
degeneration of both skeletal muscle and bone, two tissues
that are affected in IBMPFD, and provides a possible
common disease mechanism.
VCP modulates the NF-kB signaling pathway by regulating
the degradation of IkB-a. IkB-a normally retains NF-kB in an
inactive state in the cytoplasm. In response to TNF-a or
RANK-L binding, IkB-a is phosphorylated and then ubiquiti-
nated and subsequently degraded by the proteasome in a
VCP-dependent manner (41). This degradation of IkB-a
frees NF-kB to be activated by phosphorylation and then
translocate to the nucleus. VCP knockdown leads to accumu-
lation of IkB-a and decreased activation of NF-kB (43). Thus,
we hypothesized that the pathogenic mechanism of IBMPFD
may involve increased clearance of IkB-a and consequently
increased the downstream activation of NF-kB with pathologi-
cal consequences in muscle and bone.
To test this hypothesis, we evaluated NF-kB signaling in
C2C12 cells over-expressing wild-type or VCP-A232E. We
treated the cells with TNF-a (100 ng/ml) for 0, 5 or 30 min,
and monitored protein levels of IkB-a and phosphorylated
NF-kB by western blot. As expected, cells transfected with
VCP-wt showed increased clearance of IkB-a in response to
TNF-a, but the recovery of IkB-a followed roughly the
same kinetics as control cells, returning to near normal
levels by 30-min (Fig. 8A and B). In contrast, cells transfected
with VCP-A232E showed significantly greater clearance of
IkB-a that persisted through the 30-min time point (Fig. 8A
and B). Our evaluation of NF-kB activation revealed a consist-
ent pattern. Cells transfected with VCP-A232E showed signifi-
cantly increased levels of phosphorylated NF-kB (P-NF-kB)
following TNF-a treatment, and the increase persisted at
30-min (Fig. 8A and B).
To determine whether this apparent increase in NF-kB signal-
ing had functional consequences, cells were co-transfected with
VCP and a luciferase reporter construct driven by tandem
repeats of the NF-kB response element. Twenty-four hours
post-transfection, we treated C2C12 cells with increasing con-
centrations of TNF-a for 16 h. Cells transfected with
VCP-A232E showed significant increases in basal NF-kB
activity, as well as a leftward shift of the dose-response curve
indicating increased sensitivity to TNF-a (Fig. 8C). At higher
doses of TNF-a, cells expressing either VCP-wt or
VCP-A232E showed increased luciferase activity compared
with control cells, but were not statistically different from
each other (Fig. 8C). These data implicate amplification of the
NF-kB signaling pathway in the pathogenesis of IBMPFD and
suggest the possibility of common underlying mechanisms of
pathogenesis in multiple tissues affected in IBMPFD.
DISCUSSION
IBMPFD is a devastating multisystem degenerative disease,
and although several years have passed since genetic studies
have identified mutations in VCP/p97 as the cause of this
dominantly inherited disease, relatively little progress has
been made identifying the molecular mechanism(s) of patho-
genesis. VCP/p97 activity is vital to a diverse array of cellular
activities and it is likely that multiple perturbations are
initiated by disease-causing mutations and that pathogenesis
is multi-factorial and complex. Moreover, it is quite possible
that molecular pathogenesis differs in different tissues. A
prior mouse model targeted mutant VCP expression to
muscle and characterized degeneration in this tissue, but
there remained a need for an animal model faithfully recapitu-
lating the full spectrum of pathologies seen in human
IBMPFD. Here, we have presented the development and
characterization of transgenic mice in which ubiquitous
expression VCP carrying either of two distinct disease-causing
mutations (R155H or A232E) faithfully recapitulates the com-
plete IBMPFD phenotype, including involvement of muscle,
brain and bone.
Characteristics of the IBMPFD mice
Muscle weakness in VCP-R155H and VCP-A232E mice
becomes significant at 20 and 16 weeks, respectively, and is
slowly progressive (Fig. 2A). Histopathological examination
reveals classical features of IBM including myogenic
atrophy accompanied by inflammatory infiltrate and rimmed
vacuoles (Figs 2B–G and 3E). Moreover, myopathy in the
VCP-R155H and VCP-A232E mice exhibits TDP-43 pathol-
ogy that overlaps ubiquitin pathology (Fig. 3) consistent
with observations in human sporadic and inherited IBM
(26,51,52). Ultrastructural analysis of degenerating muscle
reveals loss of myofiber integrity in some sarcomeres
accompanied by markedly swollen, degenerating mitochondria
(Fig. 4C and D). VCP-R155H and VCP-A232E transgenic
mice develop behavioral abnormalities including increased
anxiety that becomes significant at 20 and 16 weeks, respect-
ively, similar in age of onset to muscle weakness (Fig. 6J and
Supplementary Material, Fig. S2). The mutant mice also
develop a deficit in novel object recognition at 14 months
(Fig. 6K). Neuropathological examination revealed wide-
spread redistribution of TDP-43 from the nucleus to cyto-
plasmic aggregates, but no nuclear inclusions of TDP-43
(Fig. 5). Moreover, double labeling indicated that cytoplasmic
TDP-43 was immunopositive for ubiquitin (Fig. 6). Radiologi-
cal evaluation of the skeletons revealed that VCP-R155H and
VCP-A232E transgenic mice develop profound osteopenia,
with some focal areas of increased radiolucency and other
areas of increased bone (Fig. 7). Expression of mutant VCP
in other tissues also—including heart, liver, kidney, spleen
and intestine—was not associated with pathology, consistent
with the selective vulnerability of muscle, brain and bone
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observed in patients with IBMPFD. This is the first complete
mouse model of IBMPFD and will be an important tool in
advancing our understanding of disease pathology. Further-
more, this model may be an important tool for understanding
sporadic forms of IBM, PDB and FTD-TDP.
Insights into pathogenesis of IBMPFD
VCP/p97 regulates the ubiquitin-dependent degradation of a
wide variety of proteins that themselves are key regulators
of discrete biological processes. In this way, VCP/p97
enables hierarchical control of numerous biological processes
by the ubiquitin-proteasome system. Disease pathogenesis
may involve very subtle alteration of native VCP/p97 func-
tion, rather than an entirely novel gain of function or dominant
negative mechanism. Because so many of the known VCP/p97
interacting proteins are themselves involved in cellular signal-
ing cascades, these small changes in VCP/p97 function may be
amplified throughout the cell, leading to wide-spread changes
in the cellular environment.
Figure 8. VCP mutant myoblasts show increased NF-kB signaling. (A) C2C12 myoblasts were transiently transfected with wild-type or mutant VCP constructs,
and treated with TNF-a (100 mg/ml) for 5 and 30 min. Cells were lysed and analyzed by western blot. Cells transfected with VCP-A232E show increased clear-
ance of IkB-a at 5 min, and levels are slower to return to normal compared with empty vector and VCP-WT controls. A corresponding increase was seen in
phosphorylated NF-kB protein levels. (B) Graphical representation of IkB-a and NF-kB protein levels relative to actin as quantified by ImageJ densitometry
shows significant changes in the rate of recovery of IkB-a levels in VCP-A232E lysates and significant increases in activation of NF-kB in response to
TNF-a. (C) C2C12 myoblasts were co-transfected with wild-type or mutant VCP and an NF-kB luciferase reporter construct, and exposed to increasing con-
centrations of TNF-a (0–100 mg/ml) overnight. Luciferase activity shows a leftward shift in the TNF-a dose response curve, with increased NF-kB driven luci-
ferase activity at lower doses. These data were analyzed by one-way ANOVA followed by post hoc Tukey’s t-test to determine differences between groups.
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All of the IBMPFD-causing mutations affect residues that
may influence interaction of the N-terminal domain of VCP/
p97 with the D1 region of the protein (53). Thus, mutations
may influence VCP/p97 binding to adaptor proteins. Specifi-
cally, we hypothesize that IBMPFD-causing mutations favor
association with some adaptors, which may contribute to
pathogenesis through a gain-of-function mechanism. Conco-
mitantly, IBMPFD-causing mutations may attenuate the inter-
action with other adaptors, contributing to pathogenesis
through a partial loss-of-function mechanism. Consistent
with this hypothesis, biochemical analysis of VCP mutants
R155H and A232E demonstrate that mutant protein appropri-
ately forms hexamers. Moreover, these mutants show 3-fold
increase in ATPase activity and also enhanced ATPase acti-
vation in response to elevated temperature (54), consistent
with amplification of a normal VCP function.
This hypothesis further predicts that mutations in VCP/p97
may have wide-ranging impact on multiple, distinct cellular
functions, whereas leaving some VCP functions intact. Consist-
ent with this hypothesis, we recently showed that disease
mutations impair an essential function of VCP in regulating
autophagy, but do not impair VCP function in endoplasmic
reticulum-associated proteasomal degradation (13). In this
study, we found evidence of additional VCP functions that
are impaired and may contribute to the complex disease pheno-
type. For example, VCP/p97 works in complex with CHIP and
UBE4B to regulate the steady state levels of the muscle chaper-
one Unc45b. Unc45b is a master regulator of myofibrillogenesis
and altered Unc45b levels (either too much or too little) cause
defects in myofiber integrity (27). We have found significantly
increased Unc45b levels in the muscles from VCP-R155H and
VCP-A232E mice, suggesting that this mechanism may contrib-
ute to myopathy in IBMPFD. VCP/p97 also regulates activity of
the NF-kB signaling pathway through regulating degradation of
IkB-a, possibly in complex with the SCF-like complex contain-
ing the E3 ligase beta-TrCP1 (55,56). We have shown that over-
expression of mutant VCP is associated with amplification of
signaling through the NF-kB pathway, implicating perturbation
of this critical signaling pathway as also contributing to disease.
Importantly, amplification of NF-kB signaling has been pre-
viously identified as the molecular defect underlying multiple
genetic forms of PDB (44). More recently, as discussed
earlier, amplification of NF-kB signaling has also been impli-
cated as a potentially important contributor to muscle disease
(49). Thus, amplification of the NF-kB signaling may be a
common underlying mechanism of pathogenesis in multiple
tissues affected in IBMPFD.
A significant challenge in future IBMPFD research will be
to further untangle the contribution of individual perturbations
caused by VCP mutations to tissue-specific disease manifes-
tations, and we believe that the mouse model presented here
provides an excellent resource in our further search for the
molecular underpinnings of IBMPFD.
MATERIALS AND METHODS
Generation of transgenic mice
Human VCP cDNA was obtained from Origene. Disease-
associated mutations R155H and A232E were introduced
using the QuickChange Site-Directed Mutagenesis Kit (Strata-
gene) as directed. The cDNA was then subcloned into the
SmaI site of pCX-A (a gift from Dr Albert R LaSpada).
DNA was microinjected into male SJL pronuclei, which
were then transferred to foster females. Founders were
screened by PCR of tail DNA and positive founders were
bred to C57/B6 animals to produce F2 progeny. Mice
were housed according to the University of Pennsylvania’s
animal care policies.
Behavioral testing
Elevated zero maze. The zero maze (Med Associates) consists
of a circular platform (6.1 cm width with a 40 cm inner diam-
eter) that is equally divided into four quadrants. Two quad-
rants on opposite sides of the platform are enclosed by walls
(20.3 cm high); the other two quadrants are open and bordered
by a lip (0.6 cm high). The maze is elevated 72.4 cm above the
floor and there is an overhead camera and tracking system to
monitor activity of the mouse. Mice were placed with all
four paws inside closed quadrant 1, facing into the closed
quadrant. Each animal was allowed 5-min on the maze, and
the maze was cleaned with 70% ethanol between animals.
Trials were recorded on video, and an observer later scored
the time spent in each of the four quadrants.
Hanging wire test. Mice were suspended by their forepaws
from a metal wire (2 mm diameter) 18 in. above a padded
cage and latency to fall was recorded with a maximum of
200 s.
Novel object recognition. Six mice from each genotype were
tested at 14 months of age. On day 1, the mice were accli-
mated to the training chamber for 5-min in the absence of
any objects. On day 2, the animals were placed in the training
chamber with two objects (a glass beaker and a block) for
5-min, and visits to each object as defined by a nose poke
within 1 cm were recorded. Finally, on day 3 the animals
were tested for their 24 h interval, and again were presented
with their familiar object (glass beaker) and a novel object
(striped block). An object preference ratio was recorded,
defined as the time spent with the novel object divided by
the time spent with the familiar object, meaning that equal pre-
ference would produce an object preference ratio of 1.
Histology
Mice were anesthetized followed by transcardial perfusion
with 4% paraformaldehyde in 0.1 M phosphate buffer. Brain,
bone and skeletal muscle were removed and post-fixed for
24 h. Tissues were either processed for paraffin embedding
or saturated with 30% sucrose (w/v) before OCT embedding
and cryostat sectioning at 4 mm.
Western blotting
Freshly isolated tissues were quickly frozen between two
blocks of dry ice and immediately crushed and resuspended
in 1 ml of tissue lysis buffer (50 mM Tris, 150 mM NaCl,
0.1% Ipegal, 10% glycerol). Protein content was determined
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by BCA assay (Promega) and equal amounts of protein were
loaded (30 mg/lane) after boiling for 5-min in 2X SDS
sample buffer. All samples were run on 8–16% Tris-glycine
gels. Unc45b antibody (Sigma) was used at a concentration
of 1:500. IkB and NF-kB antibodies (Cell Signaling) were
used at 1:1000. TDP-43 antibody (Proteintech) was used at
1:1200.
Immunohistochemistry and TEM
Paraffin-embedded brain and muscle sections were processed
with antigen unmasking solution (Vector Labs) and stained
using the Impress immunolabeling system as directed
(Vector Labs). Anti-TDP-43 antibody was used at a concen-
tration of 1:1000 and anti-ubiquitin antibody (Cell Signaling)
was used at 1:2500. For immunofluorescence, frozen sections
were permeabilized in PBS with 0.1% Triton X-100 followed
by blocking in 5% normal goat serum. Sections were incu-
bated in primary antibody overnight followed by staining
with fluorescent secondary antibodies (Molecular Probes
1:500) for 1 h at room temperature. For TEM, mice were
perfuse with 4% glutaraldehyde in 0.1 M cacodylate buffer
and were post-fixed in 1% OsO4 and en bloc stained with
1% uranyl acetate. After standard dehydration, samples were
infiltrated and embedded in Spurr low-viscosity resin (Elec-
tron Microscopy Sciences), and polymerized at 608C for
18 h. Semi-thin sections (0.5 mm) were stained with toluidine
blue, and 600–900 A˚ sections were stained in grids with Rey-
nold’s lead citrate and uranyl acetate.
Micro-CT analysis
Three animals from each genotype were anesthetized and
sacrificed, and the left and right hind limbs were fixed in
4% PFA for 24 h following perfusion. Each entire femur
was scanned using an eXplore Locus SP micro-CT scanner
(GE Healthcare, Waukesha, WI, USA). The following scan
parameters were used: tube voltage/current ¼ 80 kVp/80 mA,
beam filter ¼ 250 mm thick aluminum, integration time ¼
1.7 s, detector binning ¼ 2  2, views ¼ 400, angular
increment ¼ 0.58, signal averages ¼ 8, scan time ¼ 2 h.
Image data were reconstructed at an isotropic resolution of
16 mm. Stereological analysis was performed using Micro-
View software (GE Healthcare) to generate a volumetric
region of interest in the distal end of each femur in which tra-
becular bone was quantified. The following standard stereolo-
gical parameters were computed as averages from values
corresponding to the x, y and z axes: bone volume to total
volume ratio (bone volume fraction), bone surface to bone
volume ratio, trabecular thickness, trabecular spacing, trabecu-
lar number density (spatial frequency) and Euler number
(measure of trabecular network connectivity). For qualitative
comparisons in Figure 7, image data were displayed using
OsiriX software (www.osirix-viewer.com). In Figure 7A,
maximum intensity projection views of each distal femur
were made by projecting through 500 mm-thick slabs in the
reformatted coronal (top row) and sagittal (bottom row)
planes. In Figure 7B, both ‘red glass’ translucent and solid
color opaque volume rendering was used to show each distal
femur under identical display settings.
Cell culture
C2C12 cells were maintained in Dulbecco’s Modified Eagles
Medium with 20% fetal bovine serum in 5% CO2. Cells
were grown to 70% confluence and then transfected with
Lipofectamine 2000 according to the manufacturer’s direc-
tions. NF-kB and control luciferase reporter constructs were
obtained from Clonetech (pMetLuc2-Reporter, pNF-kB-
MetLuc2-Reporter) and activity was determined using the
accompanying ‘Ready to glow’ secreted luciferase assay kit
as directed. Luciferase activity was read using a Vector 5
plate reader.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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